Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Depreciation & Amortization (CF) (2016 - 2025)

Iradimed (IRMD) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $383722.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 94.22% to $383722.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $980186.0, a 18.36% increase, with the full-year FY2024 number at $817656.0, up 6.86% from a year prior.
  • Depreciation & Amortization (CF) was $383722.0 for Q3 2025 at Iradimed, up from $207476.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $494176.0 in Q2 2022 to a low of -$692905.0 in Q4 2022.
  • A 5-year average of $233981.7 and a median of $207476.0 in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 279.23% in 2022, then surged 129.64% in 2023.
  • Iradimed's Depreciation & Amortization (CF) stood at $386600.0 in 2021, then tumbled by 279.23% to -$692905.0 in 2022, then soared by 129.64% to $205375.0 in 2023, then dropped by 5.12% to $194866.0 in 2024, then surged by 96.92% to $383722.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Depreciation & Amortization (CF) are $383722.0 (Q3 2025), $207476.0 (Q2 2025), and $194122.0 (Q1 2025).